Cubist Pharms Company Profile

What is the competitive landscape for CUBIST PHARMS

CUBIST PHARMS has seven approved drugs.

There are twenty-seven US patents protecting CUBIST PHARMS drugs.

There are three hundred and fifty-five patent family members on CUBIST PHARMS drugs in fifty-three countries and fifty-six supplementary protection certificates in nineteen countries.

Summary for Cubist Pharms

International Patents:	355
US Patents:	27
Tradenames:	6
Ingredients:	5
NDAs:	7

Drugs and US Patents for Cubist Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Cubist Pharms Llc	DIFICID	fidaxomicin	FOR SUSPENSION;ORAL	213138-001	Jan 24, 2020		RX	Yes	Yes	9,808,530*PED				Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	TABLET;ORAL	205435-001	Jun 20, 2014		RX	Yes	Yes	10,065,947		Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	TABLET;ORAL	205435-001	Jun 20, 2014		RX	Yes	Yes	9,988,406		Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes	8,420,676		Y	Y
Cubist Pharms Llc	SIVEXTRO	tedizolid phosphate	POWDER;INTRAVENOUS	205436-001	Jun 20, 2014		RX	Yes	Yes	9,988,406		Y
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003		DISCN	No	No
Cubist Pharms Llc	ZERBAXA	ceftolozane sulfate; tazobactam sodium	POWDER;INTRAVENOUS	206829-001	Dec 19, 2014		RX	Yes	Yes	8,968,753*PED				Y

Expired US Patents for Cubist Pharms

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	6,852,689
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	5,912,226
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	RE39071
Cubist Pharms	ENTEREG	alvimopan	CAPSULE;ORAL	021775-001	May 20, 2008	5,250,542
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	6,468,967
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-001	Sep 12, 2003	8,058,238
Cubist Pharms Llc	CUBICIN	daptomycin	POWDER;INTRAVENOUS	021572-002	Sep 12, 2003	8,129,342

Paragraph IV (Patent) Challenges for CUBIST PHARMS drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
	For Injection	500 mg/vial		2008-11-19
	Tablets	200 mg		2015-05-27
	Capsules	12 mg		2017-06-16

International Patents for Cubist Pharms Drugs

Country	Patent Number	Estimated Expiration
Spain	2290498
South Korea	20050053598
Japan	2016147874
Dominican Republic	P2012000140
South Korea	20050084897
Taiwan	I548414
Georgia, Republic of	P201706769

Supplementary Protection Certificates for Cubist Pharms Drugs

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1539977	201540017	Slovenia		PRODUCT NAME: FIDAXOMICIN; NATIONAL AUTHORISATION NUMBER: EU/1/11/733/001-004; DATE OF NATIONAL AUTHORISATION: 20111205; AUTHORITY FOR NATIONAL AUTHORISATION: EU
1115417	CA 2006 00018	Denmark		PRODUCT NAME: DAPTOMYCIN
1699784	52/2015	Austria		PRODUCT NAME: TEDIZOLID, WAHLWEISE IN DER FORM EINES ESTERS, INSBESONDERE EINES PHOSPHATS, ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ HIEVON; REGISTRATION NO/DATE: EU/1/15/991 20150323
1556389	C01556389/01	Switzerland		PRODUCT NAME: CEFTOLOZAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 65472 03.03.2016
1539977	92684	Luxembourg		PRODUCT NAME: FIDAXOMICINE OU SON SEL PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/11/733/001-002-004 - DIFICLIR
1556389	CR 2016 00004	Denmark		PRODUCT NAME: CEFTOLOZAN ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, SAERLIGT ET SVOVLSYRESALT; REG. NO/DATE: EU/1/15/1032/001 20150922
1699784	C300759	Netherlands		PRODUCT NAME: TEDIZOLID, DESGEWENST IN DE; REGISTRATION NO/DATE: EU/1/15/991 20150323

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

• Cubist Pharms
• Cubist Pharms Llc